You just read:

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

News provided by

InMed Pharmaceuticals Inc.

Dec 09, 2019, 07:30 ET